Author:
Liu Jinrong,Zhao Fei,Lu Jie,Xu Hui,Liu Hui,Tang Xiaolei,Yang Haiming,Zhang Jianzhong,Zhao Shunying
Abstract
Abstract
Background
An increased number of refractory mycoplasma pneumoniae (MP) pneumonia (MPP) cases have been reported. However the duration of MP infection in lower airway and the course of anti-MP treatment remains unclear.
Methods
We retrospectively reviewed the medical records of 94 MPP children. Patients were classified into two groups. The long-term group (Group LT) was defined as bronchoalveolar lavage fluid (BALF) remained MP-positive by PCR after 30 days of the disease course. The non-long-term group (Group NLT) was defined as BALF became MP-negative by PCR within 30 days of disease and patients who only needed one bronchoscopy lavage therapy. MP loads, clinical outcomes were analyzed along with other clinical measurements.
Results
The average levels of inflammatory markers such as C reactive protein and lactate dehydrogenase in Group LT were significantly higher than those in Group NLT. Airway and lung damage in Group LT were more severe than Group NLT. 28 patients developed necrotizing pneumonia and 8 patients developed pulmonary embolism in Group LT. Mean maximum MP loads in BALF were 107.46 ± 0.93 and 104.86 ± 0.93 in Groups LT and NLT, respectively. There was persistent MP DNA in Group LT, even lasted for 120 days. One severe MPP patient in Group LT had MP-associated bloodstream infection. After 3 months of follow-up, chest imaging revealed incomplete absorption of pulmonary consolidation in 33 patients of Group LT [including 13 airway obliterans (AO) patients] and in 7 patients of Group NLT (including 2 AO patients).
Conclusion
MP loads of BALF were associated with the subsequent duration of MP DNA in lower airway. High MP loads and persistent long-term MP DNA in lower airway were associated with severity of pediatric MPP.
Funder
Beijing Municipal and Commission Health and Family Planning
National Natural Science Foundation of China
the Major Infectious Diseases Such as AIDS and Viral Hepatitis Prevention and Control Technology Major Projects
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Chen L, Liu J, Zhao S, et al. Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children. Zhonghua er ke za zhi = Chinese J Pediatr. 2014;52:172.
2. Miyashita N, Kawai Y, Inamura N, et al. Setting a standard for the initiation of steroid therapy in refractory or severe mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2014;21:153–60.
3. Daxboeck F, Eisl B, Burghuber C, et al. Fatal mycoplasma pneumoniae pneumonia in a previously healthy 18-year-old girl. Wien Klin Wochenschr. 2007;119:379–84.
4. Leong MA, Nachajon R, Ruchelli E, et al. Bronchitis obliterans due to mycoplasma pneumonia. Pediatr Pulmonol. 1997;23:375–81.
5. Wang M, Wang Y, Yan Y, et al. Clinical and laboratory profiles of refractory mycoplasma pneumoniae pneumonia in children. Int J Infect Dis. 2014;29:18–23.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献